An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody...

Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza. The Company’s proprietary oligoDOM®...

Altimmune, Inc. announced today dosing of the first patient in the Company’s Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. “NasoShield is the only single...

A national study measuring parental attitudes toward vaccinations found 6.1% were hesitant about routine childhood immunizations while nearly 26% were hesitant about the influenza vaccine. “Our...

Bavarian Nordic A/S announced today topline results from the the first-in-human trial of MVA-BN® WEV, a prophylactic vaccine candidate against three equine encephalitis viruses (western, eastern and...

Valneva SE, a specialty vaccine company, announced today the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed medical journal The...

Clinical-stage, natural killer cell-based therapeutics company, NantKwest and  ImmunityBio, a privately-held immunotherapy company announced ImmunityBio has been selected to participate in Operation Warp...

Biotechnology company, Novavax, Inc. today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein...

Clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, Inc.,  announced Monday positive interim clinical data of mRNA-1273, its vaccine candidate against...

The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for...